PPHM Opinions 03/06/2016 02:43:55 $PPHM
Published on Feb 29, 2016
Understanding all of the emerging immunotherapy options for CLL patients can be difficult. Drs. Zeev Estrov, Michael Keating, and Nicole Lamanna explore the strategies of various checkpoint inhibitors and CAR-T cell therapies and how they work in a balancing act between both suppressing and stimulating your immune system.
Understanding Emerging CLL Immunotherapy Options
..at 2 min 10 sec mark pay attention:
"So how can we fix it.......CD8 cells, they produce on the surface proteins that prevent the interaction between the T-Lympocytes and the cancer cells... and when we attack these protected proteins with antibodies suddenly the T-Lymphocytes can do their job..."
(I'd listen to the entire video... especially the end)
https://www.youtube.com/watch?v=l8vnvxfy3YQ
Now read this post and when you finish, you'll realize that the above quote is referring to flipped PS binding proteins...and Peregrine has had this patent on PS Targeting and about 10 years head start on other companies, with BetaBodies coming their way this week for a patent. The foundation has been being built surrounding PS Targeting and the betabody patent work will move much faster than most think.
Published on Feb 29, 2016
Understanding all of the emerging immunotherapy options for CLL patients can be difficult. Drs. Zeev Estrov, Michael Keating, and Nicole Lamanna explore the strategies of various checkpoint inhibitors and CAR-T cell therapies and how they work in a balancing act between both suppressing and stimulating your immune system.
Understanding Emerging CLL Immunotherapy Options
..at 2 min 10 sec mark pay attention:
"So how can we fix it.......CD8 cells, they produce on the surface proteins that prevent the interaction between the T-Lympocytes and the cancer cells... and when we attack these protected proteins with antibodies suddenly the T-Lymphocytes can do their job..."
(I'd listen to the entire video... especially the end)
https://www.youtube.com/watch?v=l8vnvxfy3YQ
Now read this post and when you finish, you'll realize that the above quote is referring to flipped PS binding proteins...and Peregrine has had this patent on PS Targeting and about 10 years head start on other companies, with BetaBodies coming their way this week for a patent. The foundation has been being built surrounding PS Targeting and the betabody patent work will move much faster than most think.
